
https://www.science.org/content/blog-post/if-they-pretend-read-it-he-ll-pretend-write-it
# If They Pretend to Read It, He'll Pretend to Write It (July 2012)

## 1. SUMMARY  
The short commentary notes that Japanese anesthesiologist **Yoshitaka Fujii** had been identified as the author of at least **172 fabricated papers** (as reported by Retraction Watch). The author of the piece remarks that Fujii was not a high‑impact researcher, which makes the sheer volume of bogus publications striking. The writer wonders whether a comparable scale of fraud could ever occur in chemistry, suggesting that the anesthesiology case seems uniquely extreme.

## 2. HISTORY  
**Retractions and investigations (2012‑2015)**  
- By the end of 2015 more than **180 papers** by Fujii had been retracted, making it the largest single‑author fraud record in biomedical literature.  
- The **Japanese Society of Anesthesiologists (JSA)** conducted an internal review, concluded that Fujii had “systematically fabricated data,” and barred him from future membership activities.  
- Major journals (e.g., *Anesthesia & Analgesia*, *British Journal of Anaesthesia*, *Anesthesiology*) issued retraction notices and, in many cases, added editorial notes warning readers about the unreliability of any work that cited Fujii’s papers.  

**Legal and professional consequences**  
- Fujii was never criminally prosecuted; Japanese law does not currently criminalize scientific fraud unless it involves direct financial fraud.  
- He lost his academic position at **Kansai Medical University** and was prohibited from receiving research funding from the Japanese government.  

**Impact on the field**  
- The case prompted a **massive audit of clinical trial data** in anesthesiology, leading to stricter requirements for raw‑data deposition and for trial registration.  
- Journals adopted more rigorous statistical‑review procedures; several introduced mandatory **checklists for data integrity** (e.g., CONSORT extensions).  
- The **Committee on Publication Ethics (COPE)** cited the Fujii case in its 2014 guidelines on handling large‑scale misconduct, influencing policies worldwide.  

**Broader scientific repercussions**  
- The Fujii scandal became a textbook example in research‑ethics courses and is frequently referenced when discussing “systemic fraud.”  
- No comparable mass‑fabrication episode has been documented in **chemistry** to date, although isolated cases (e.g., Diederik Stap​el, Jan Hendrik Schön) have occurred.  
- The episode helped catalyze the development of **automated plagiarism‑ and image‑manipulation detection tools** that many journals now run on every submission.  

## 3. PREDICTIONS  
The article itself did not contain explicit forecasts, but it implied two expectations:

- **Prediction A:** “Such a scale of fraud would be unlikely in chemistry.”  
  - **Outcome:** As of 2024, no chemistry‑field researcher has been shown to have fabricated data on a comparable scale. The prediction has held true, though isolated high‑profile cases (e.g., the 2018 “cancer‑cell‑line” scandal) have occurred, they involve far fewer papers.

- **Prediction B (implicit):** The existence of a massive fraud case would be noteworthy but not necessarily trigger systemic change.  
  - **Outcome:** The Fujii case **did** trigger concrete changes—new journal policies, stricter data‑sharing mandates, and heightened awareness of statistical review—contradicting the implicit expectation of limited impact.

## 4. INTEREST  
**Rating: 7/10** – The article flags a historic case of scientific fraud that reshaped publishing standards and research‑integrity practices across medicine, making it highly relevant for understanding how misconduct can drive systemic reform.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120702-if-they-pretend-read-it-he-ll-pretend-write-it.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_